CAS: 2449301-27-1

GSK2643943A is an investigational drug, which is a product of GlaxoSmithKline's extensive research efforts. It is a small molecule inhibitor targeting specific cellular pathways involved in tumor growth and proliferation. This compound is designed to selectively inhibit kinase signaling, a process critical for the survival and metastasis of cancer cells. By disrupting these pathways, GSK2643943A aims to impede cancer progression, offering a potential new avenue for therapeutic intervention in oncology. The mechanism of action of GSK2643943A involves the inhibition of specific kinases, which are enzymes that play a pivotal role in signal transduction processes within cells. By blocking these kinases, the drug can effectively interfere with the intracellular signaling networks that cancer cells rely on for growth and survival. In preclinical and early clinical studies, GSK2643943A has shown promise in attenuating tumor growth in various cancer models, making it a candidate for further exploration in the treatment of cancers with deregulated kinase activity. Its development underscores the ongoing efforts to identify targeted therapies that can provide more effective and personalized treatment options for cancer patients.

GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor, with an IC 50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy.

GSK2643943A